Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia:: Consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia

被引：237

作者：

Kyle, RA

Treon, SP

Alexanian, R

Barlogie, B

Björkholm, M

Dhodapkar, M

Lister, TA

Merlini, G

Morel, P

Stone, M

Branagan, AR

Leblond, W

机构：

[1] Harvard Univ, Sch Med, Waldenstroms Macroglobulinemia Program, Dana Farber Canc Inst, Boston, MA 02215 USA

[2] Mayo Clin, Rochester, MN USA

[3] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Myeloma Inst Res & Therapy, Little Rock, AR USA

[5] Karolinska Hosp & Inst, Dept Med, Stockholm, Sweden

[6] Rockefeller Univ, Lab Tumor Immunol & Immunotherapy, New York, NY 10021 USA

[7] St Bartholomews Hosp, Dept Oncol, London, England

[8] Univ Hosp Pavia, Biotechnol Res Labs, IRCCS, Policlin San Matteo, Pavia, Italy

[9] Univ Pavia, Dept Biochem, I-27100 Pavia, Italy

[10] Ctr Hosp Schaffner, Serv Hematol Clin, Lens, France

[11] Baylor Charles A Sammons Canc Ctr, Dallas, TX USA

[12] Hop La Pitie Salpetriere, Dept Hematol, Paris, France

来源：

SEMINARS IN ONCOLOGY | 2003年 / 30卷 / 02期

关键词：

D O I：

10.1053/sonc.2003.50038

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：116 / 120

页数：5

共 18 条

[1] Asymptomatic Waldenstrom's macroglobulinemia [J].

Alexanian, R ;

Weber, D ;

Delasalle, K ;

Cabanillas, F ;

Dimopoulos, M .

SEMINARS IN ONCOLOGY, 2003, 30 (02) :206-210

[2]

Andriko JAW, 1997, CANCER, V80, P1926, DOI 10.1002/(SICI)1097-0142(19971115)80:10<1926::AID-CNCR9>3.0.CO

[3]

2-L

[4]

BROUET JC, 1975, ACTUAL HEMATOL, V9, P38

[5] Smouldering Waldenstrom's macroglobulinemia: Factors predicting evolution to symptomatic disease [J].

Cesana, C ;

Miqueleiz, S ;

Bernuzzi, P ;

Tresoldi, E ;

Rossi, V ;

D'Avanzo, G ;

Filippini, D ;

Morra, E .

SEMINARS IN ONCOLOGY, 2003, 30 (02) :231-235

[6] Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003) [J].

Dhodapkar, MV ;

Jacobson, JL ;

Gertz, MA ;

Rivkin, SE ;

Roodman, GD ;

Tuscano, JM ;

Shurafa, M ;

Kyle, RA ;

Crowley, JJ ;

Barlogie, B .

BLOOD, 2001, 98 (01) :41-48

[7] Waldenstrom's macroglobulinemia: Clinical features, complications, and management [J].

Dimopoulos, MA ;

Panayiotidis, P ;

Moulopoulos, LA ;

Sfikakis, P ;

Dalakas, M .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) :214-226

[8]

DIMOPOULOS MA, 1994, BLOOD, V83, P1452

[9] PROGNOSTIC FACTORS IN WALDENSTROM MACROGLOBULINEMIA - A REPORT OF 167 CASES [J].

FACON, T ;

BROUILLARD, M ;

DUHAMEL, A ;

MOREL, P ;

SIMON, M ;

JOUET, JP ;

BAUTERS, F ;

FENAUX, P .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (08) :1553-1558

[10] Waldenstrom macroglobulinaemia:: presenting features and outcome in a series with 217 cases [J].

García-Sanz, R ;

Montoto, S ;

Torrequebrada, A ;

de Coca, AG ;

Petit, J ;

Sureda, A ;

Rodríguez-García, JA ;

Massó, P ;

Pérez-Aliaga, A ;

Monteagudo, MD ;

Navarro, I ;

Moreno, G ;

Toledo, C ;

Alonso, A ;

Besses, C ;

Besalduch, J ;

Jarque, I ;

Salama, P ;

Rivas, JAH ;

Navarro, B ;

Bladé, J ;

Miguel, JFS .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (03) :575-582

← 1 2 →